AR118619A1 - Anticuerpos de unión a pd-1 - Google Patents

Anticuerpos de unión a pd-1

Info

Publication number
AR118619A1
AR118619A1 ARP200100982A ARP200100982A AR118619A1 AR 118619 A1 AR118619 A1 AR 118619A1 AR P200100982 A ARP200100982 A AR P200100982A AR P200100982 A ARP200100982 A AR P200100982A AR 118619 A1 AR118619 A1 AR 118619A1
Authority
AR
Argentina
Prior art keywords
antibodies
binding
neutralize
antigen
seq
Prior art date
Application number
ARP200100982A
Other languages
English (en)
Spanish (es)
Inventor
Shengfeng Li
Shizhong Liang
Shujun Pei
Jian Lin
Haitao Yue
Original Assignee
Bio Thera Solutions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Thera Solutions Ltd filed Critical Bio Thera Solutions Ltd
Publication of AR118619A1 publication Critical patent/AR118619A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
ARP200100982A 2019-04-10 2020-04-08 Anticuerpos de unión a pd-1 AR118619A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910286677 2019-04-10

Publications (1)

Publication Number Publication Date
AR118619A1 true AR118619A1 (es) 2021-10-20

Family

ID=72750942

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100982A AR118619A1 (es) 2019-04-10 2020-04-08 Anticuerpos de unión a pd-1

Country Status (7)

Country Link
US (1) US12466887B2 (enExample)
EP (1) EP3931223A4 (enExample)
JP (1) JP7641910B2 (enExample)
CN (2) CN117603355A (enExample)
AR (1) AR118619A1 (enExample)
TW (1) TWI916327B (enExample)
WO (1) WO2020207432A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022007807A1 (zh) * 2020-07-07 2022-01-13 百奥泰生物制药股份有限公司 双特异性抗体及其应用
CN116437926B (zh) * 2020-10-11 2026-01-20 百奥泰生物制药股份有限公司 抗pd-1抗体在联合用药中的应用
EP4353746A4 (en) * 2021-06-11 2024-12-04 Guangdong Fapon Biopharma Inc. Anti-pd-1 humanized antibody or antigen-binding fragment thereof and application thereof
WO2025140324A1 (zh) 2023-12-26 2025-07-03 百奥泰生物制药股份有限公司 抗pd-1抗体联合化疗剂在治疗肿瘤中的用途
WO2025190251A1 (zh) * 2024-03-12 2025-09-18 百奥泰生物制药股份有限公司 抗trop2抗体药物偶联物和pd-1拮抗剂联合治疗实体瘤的用途
CN120919340A (zh) * 2024-05-09 2025-11-11 百奥泰生物制药股份有限公司 抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用
CN121015902A (zh) * 2024-05-27 2025-11-28 百奥泰生物制药股份有限公司 抗trop2抗体药物偶联物和抗pd-l1/cd47双特异抗体联合治疗肿瘤的用途
CN121754666A (zh) * 2024-09-30 2026-03-31 百奥泰生物制药股份有限公司 一种抗pd-1抗体制剂及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
PT2170959E (pt) * 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PL3368572T5 (pl) 2015-10-02 2026-07-20 Les Laboratoires Servier Przeciwciała anty-PD-1 oraz kompozycje
EP3604539A4 (en) * 2017-03-27 2020-12-23 National University Corporation Hokkaido University ANTI-PD-L1 ANTIBODY FOR DETECTION OF PD-L1
WO2018217227A1 (en) * 2017-05-24 2018-11-29 Immunomedics, Inc. Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1
CN108997499B (zh) * 2018-09-12 2020-07-31 首都医科大学附属北京胸科医院 一种抗人pd-l1抗体及其应用

Also Published As

Publication number Publication date
EP3931223A1 (en) 2022-01-05
EP3931223A4 (en) 2023-07-12
US12466887B2 (en) 2025-11-11
JP7641910B2 (ja) 2025-03-07
TW202104262A (zh) 2021-02-01
CN111808190A (zh) 2020-10-23
US20220204623A1 (en) 2022-06-30
CN111808190B (zh) 2023-12-12
CN117603355A (zh) 2024-02-27
WO2020207432A1 (en) 2020-10-15
TWI916327B (zh) 2026-03-01
JP2022538375A (ja) 2022-09-02

Similar Documents

Publication Publication Date Title
AR110979A1 (es) Moléculas de unión a cd70 y métodos de uso de las mismas
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
CY1122020T1 (el) Μορια δεσμευσης σε cd3 ικανα να δεσμευονται σε ανθρωπινα και μη ανθρωπινα cd3
CY1119964T1 (el) Αναστολεις οδου σηματοδοτησης notch και χρηση αυτων στη θεραπευτικη αγωγη καρκινων
CO2018006299A2 (es) Compuestos novedosos
SA523440043B1 (ar) أجسام مضادة ضد cd3 إبسيلون جديدة
MY202516A (en) Antibodies to tigit
CR20160599A (es) Diacuerpos Enlazados Covalentemente que tienen Inmunoreactividad con PD-1 y LAG-3, y Métodos de Uso de los Mismos
CY1124456T1 (el) Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων
BR112018015754A2 (pt) anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1
AR075504A1 (es) Moleculas de anticuerpos que tienen especificidad para el ox40 humano
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
EA201792307A1 (ru) Способы репарации и регенерации тканей
EA201790465A1 (ru) Антитела, композиции и применение
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
NZ755083A (en) Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
CO6700829A2 (es) Moduladores novedosos y métodos de uso
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
EP4442270A3 (en) Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2024001067A (es) Composicion farmaceutica y uso.
AR106307A1 (es) Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos